✦ LIBER ✦

P279 Reduction of hepatocellular carcinoma recurrence by pegylated interferon alpha-2b plus ribavirin treatment for chronic hepatitis C patients

✍ Scribed by Furusyo, N.; Murata, M.; Ogawa, E.; Nomura, H.; Hayashi, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1145 IMPACT OF PEGYLATED INTERFERON a2B

✍ Ogawa, E.; Furusyo, N.; Kajiwara, E.; Takahashi, K.; Nomura, H.; Tanabe, Y.; Sat 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Treatment of chronic hepatitis C in HIV

✍ A. Cargnel; E. Angeli; A. Mainini; A. Casella; G. Gubertini; R. Giorgi; G. Orlan 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 156 KB

P.260 Peginterferon alpha-2b plus ribavi

✍ R.M. El-Wakil; M.F. Montasser; M.A. Mansour; T.A. Salman; M.H. El-Batanony; E.H. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 256 KB

Pegylated interferon alpha 2b (PEG IFN)

✍ M. Manns; J.G. Mc Hutchison; S. Gordorn; V. Rustgi; M.V. Lee; M.L. Ling; M. Coha 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Cost-effectiveness of peginterferon alph

✍ Uwe Siebert; Gaby Sroczynski; Siegbert Rossol; Juergen Wasem; Ulrike Ravens-Sieb 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Pegylated interferon α-2b plus ribavirin

✍ Esther Voigt; Christian Schulz; Gerd Klausen; Joerg Goelz; Stefan Mauss; Guenthe 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 162 KB